The effects of ertugliflozin on β-cell function: Pooled analysis from four phase 3 randomized controlled studies

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) is characterized by impaired beta-cell function.
• Ertugliflozin, an SGLT2 inhibitor, is used to manage T2DM.
• Understanding predictors and mediators of treatment response is crucial for optimizing T2DM management.

Purpose of the Study:

• To identify predictors and mediators of changes in beta-cell function during ertugliflozin treatment in T2DM patients.
• To analyze the impact of ertugliflozin on both fasting and postprandial beta-cell function.

Main Methods:

• Pooled data from four Phase 3 clinical trials involving T2DM patients treated with ertugliflozin or placebo.
• Assessment of beta-cell function using Homeostatic Model Assessment of Beta-cell Function (HOMA-%β) and C-peptide index at week 26.
• Linear and multiple regression analyses to identify predictors and mediators of HOMA-%β changes.

Main Results:

• Ertugliflozin significantly improved fasting beta-cell function (HOMA-%β) compared to placebo (14.7% vs. -0.4%).
• No significant improvement in postprandial beta-cell function was observed.
• Improvements in HOMA-%β were correlated with changes in HbA1c and body weight, and predicted by baseline FPG, HbA1c, HOMA-IR, and HOMA-%β.

Conclusions:

• Ertugliflozin treatment enhances fasting beta-cell function in T2DM patients.
• Baseline glycemic control and insulin resistance influence the response to ertugliflozin.
• Further research may explore mechanisms underlying these observed changes in beta-cell function.